EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Translation of Microneedles for Diabetes Drug Delivery and Metabolic Monitoring

Yulan Cai, Hongyu Chai, Feng Zeng, Chuyu Liu

Pharmaceutics · 03.11.2026 · 18 (11) · 1420

DOI: 10.3390/pharmaceutics18111420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.11.2026. Verfasst von Yulan Cai und 3 weiteren Autor:innen. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Joint Fund of Zunyi Science and Technology Bureau, Zunyi Municipal Science and Technology Plan Project.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microneedles provide access to skin for peptide delivery and metabolic sensing, but insertion alone does not establish reliable treatment. This narrative review examines the evidence linking microneedle design to clinical claims in diabetes and identifies requirements for translation. Targeted literature retrieval distinguishes human delivery and sensing studies from animal and analytical experiments. Human hollow-microneedle studies show faster insulin absorption than subcutaneous administration, although improvement in primary glycemic outcomes is inconsistent. Responsive insulin and glucagon patches, incretin depots, and integrated sensing–delivery systems remain predominantly preclinical. Human sensing studies provide quantitative feasibility data, but accuracy depends on calibration, reference methods, population, and wear duration. We assess bioactive deposited dose separately from nominal loading, prospective decision accuracy separately from analytical agreement, and commanded delivery separately from verified exposure. Application mechanics, residual drug, local interference, manufacturing, and usability inform a proposed validation framework mapped to relevant standards and regulatory documents. This mapping is conceptual and does not constitute regulatory validation. The review identifies product-specific experiments needed to establish reproducible exposure, dependable measurements, and benefit against appropriate comparators. It does not infer human effectiveness from animal glucose lowering or assign one development pathway to all microneedle architectures.

Förderung

  • National Natural Science Foundation of China
  • Joint Fund of Zunyi Science and Technology Bureau
  • Zunyi Municipal Science and Technology Plan Project
  • Guizhou Provincial Department of Science and Technology Basic Research Program Youth Guidance Project
  • Guizhou Science and Technology Association Youth Science and Technology Talent Promotion Project
  • Zunyi Medical University Future Clinical Medical Experts Training Program
  • High-Level Talent Fund of the Second Affiliated Hospital of Zunyi Medical University

Zitieren

APA

Cai, Y., Chai, H., Zeng, F., & Liu, C. (2026). Clinical Translation of Microneedles for Diabetes Drug Delivery and Metabolic Monitoring. Pharmaceutics, 18(11), 1420. https://doi.org/10.3390/pharmaceutics18111420

Vancouver

Cai Y, Chai H, Zeng F, Liu C. Clinical Translation of Microneedles for Diabetes Drug Delivery and Metabolic Monitoring. Pharmaceutics. 2026;18(11):1420. doi:10.3390/pharmaceutics18111420

BibTeX
@article{Cai2026,
  author = {Cai, Yulan and Chai, Hongyu and Zeng, Feng and Liu, Chuyu},
  title = {Clinical Translation of Microneedles for Diabetes Drug Delivery and Metabolic Monitoring},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1420},
  doi = {10.3390/pharmaceutics18111420}
}
Kostenlos starten →